Webinar replay

After the Biotech Bubble Bursts

After a decade where deal volumes expanded, biotech valuations exploded, and venture capital flooded the biopharma market like never before, the public biotech bubble has burst. So, now what? Pharma will still seek external innovation, biotechs will still need investment, but what will the post-bubble landscape look like and how can innovative science successfully emerge?

Analyst and journalist Melanie Senior joins long-time biopharma investor Stephan Christgau, Founding Partner at EIR Ventures, Dr. Steven Cohen, Executive Director at Daiichi Sankyo, and Dylan van Haaften, Managing Director at Bryan, Garnier & Co. to discuss what a bursting biotech bubble means for dealmaking, innovation, and the industry. They discussed what to expect in the investment market in the year ahead, where investments will continue to grow and where they may dry up, and how biotechs and pharma companies can position themselves for success in a post-bubble market.

Watch this replay to get expert insights from our panelists:
melanie senior
Melanie Senior
Analyst and Journalist
Stephan Christgau
Stephan Christgau
Founding Partner
EIR Ventures
steven cohen
Steven Cohen
Executive Director
Daiichi Sankyo
dylan v haaften
Dylan van Haaften
Managing Director
Bryan, Garnier & Co.

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.

About Inova

Inova accelerates partnering for the future of medicine. Our cloud-based solutions help life science companies manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and innovative biotechs already use Inova.